dupilumab + topical corticosteroids

Dupilumab + topical corticosteroids is a combination therapy used primarily for the treatment of moderate-to-severe atopic dermatitis, especially in patients not adequately controlled with topical therapies alone. **Dupilumab** is a fully human monoclonal antibody that inhibits interleukin-4 receptor alpha (IL-4Rα), thereby blocking IL-4 and IL-13 signaling—key drivers of type 2 (Th2) mediated inflammation. **Topical corticosteroids** are synthetic glucocorticoids that exert anti-inflammatory, immunosuppressive, and antiproliferative effects by acting as agonists at the glucocorticoid receptor. Combination therapy targets complementary pathogenic mechanisms in atopic dermatitis: dupilumab reduces Th2-mediated inflammation, while corticosteroids broadly suppress cutaneous inflammatory responses at the site of application. The combination is well-studied and approved for moderate-to-severe atopic dermatitis in adults and children, with evidence for significant improvements in disease severity, pruritus, and quality of life[1][4][6].

Brand names

Dupixent

Other names

dupilumab and topical corticosteroidsdupilumab plus TCS